XTLB - XTL Biopharmaceutica...

XTL Biopharmaceuticals Ltd.

XTLB

NASDAQ

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

2.07 USD

-0.02 (-0.966%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Operating Data Balance Sheet Free Cash Flow Free Cash Flow Buildup Terminal Value Intrinsic Value Equity Value WACC

FMP

Home Terms of Service Privacy Policy Blog Careers FAQs Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.